PBYI Q3 2019 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$299M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$56M-9.9% YoY

Gross Profit

$47M83.3% margin

Operating Income

-$14M-25.5% margin

Net Income

-$17M-30.0% margin

EPS (Diluted)

$-0.43

QoQ Revenue Growth

+4.6%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$232M

Total Liabilities

$215M

Stockholders' Equity

$17M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$56M	$63M	-9.9%
Gross Profit	$47M	$54M	-12.3%
Operating Income	-$14M	-$11M	-27.4%
Net Income	-$17M	-$14M	-19.0%

Revenue Segments

Product

$53M95%

License

$3M5%

Royalty

$120,0000%